ENHANCED EXPRESSION OF A TUMOR-CELL-DERIVED COLLAGENASE-STIMULATORY FACTOR IN UROTHELIAL CARCINOMA - ITS USEFULNESS AS A TUMOR-MARKER FOR BLADDER CANCERS
ENHANCED EXPRESSION OF A TUMOR-CELL-DERIVED COLLAGENASE-STIMULATORY FACTOR IN UROTHELIAL CARCINOMA - ITS USEFULNESS AS A TUMOR-MARKER FOR BLADDER CANCERS
复制标题
DOI：
10.1002/ijc.2910550105
复制
发表时间：
1993-08-19
影响因子：
6.4
通讯作者：
KOONO, M
中科院分区：
文献类型：
--
作者：
MURAOKA, K;NABESHIMA, K;KOONO, M
一种小鼠单克隆抗体（MAb） EIIF4，先前从LX-I型人肺癌细胞中针对肿瘤细胞衍生的胶原酶刺激因子（TCSF）提出，已被用于确定TCSF在人非肿瘤性尿路上皮和膀胱肿瘤中的表达和分布。免疫组化法检测27/28例膀胱移行细胞癌（TCC） TCSF，其中23例TCSF阳性符合客观标准。来自22个个体的28个非肿瘤性尿路上皮中有24个。经此标准判定为TCSF阴性。然而，在非肿瘤性尿路上皮中经常观察到局限于表面伞状细胞的TCSF免疫染色。在膀胱癌中，TCSF在大多数情况下存在于大多数细胞中，包括侵袭前。免疫电镜证实其在细胞膜上的定位。组织提取物的免疫印迹也证实了TCSF在膀胱肿瘤中的高表达，而在非肿瘤性尿路上皮中不表达。此外，EIIF4免疫染色鉴定了从膀胱冲洗或空尿中获得的肿瘤细胞，并且比常规细胞学检测到更多的TCC病例。由于TCSF免疫染色即使在低级别TCC中也呈阳性（免疫组织化学和免疫细胞化学在4/5级TCC中），因此将TCSF免疫染色应用于尿细胞学似乎有望成为TCC患者临床评估中常规方法的有价值的辅助手段。(C) 1993 Wiley-Liss, Inc。
A mouse monoclonal antibody (MAb) EIIF4, previously raised against the tumor-cell-derived collagenase-stimulatory factor (TCSF) from LX-I human lung-carcinoma cells, has been used to define the expression and distribution of TCSF in human non-neoplastic urothelium and tumors of the urinary bladder. Immunohistochemically, TCSF was detected in 27/28 transitional-cell carcinomas (TCC) of the bladder, of which 23 were judged to be positive for TCSF according to objective criteria. Twenty-four of 28 non-neoplastic urothelium from 22 individuals were. judged to be negative for TCSF by this criteria. However, TCSF immunostaining that was confined to the superficial umbrella cells was frequently observed in non-neoplastic urothelium. In bladder carcinomas, TCSF was in most cases demonstrated in the majority of cells, including at the invasion front. Its localization to the cell membrane was demonstrated by immunoelectron microscopy. The high level of expression of TCSF in bladder tumors, but not in non-neoplastic urothelium, was also demonstrated by immunoblotting of tissue extracts. Furthermore, EIIF4 immunostaining identified tumor cells obtained from bladder washings or voided urine and detected more TCC cases than conventional cytology. Since TCSF immunostaining was positive even in low-grade TCC (immunohistochemically and immunocytochemically in 4/5 TCC grade I), the application of TCSF immunostaining to urine cytology appears promising as a valuable adjunct to conventional methods in the clinical evaluation of patients with TCC. (C) 1993 Wiley-Liss, Inc.